Ara
Toplam kayıt 987, listelenen: 981-987
Open-label, randomized, phase 3 study of coformulated favezelimab and pembrolizumab versus chemotherapy in patients with relapsed or refractory classical hodgkin lymphoma refractory to anti-PD-1 therapy: Keyform-008
(American Society of Hematology, 2023)
Background: The importance of PD-1 therapy in relapsed or refractory (R/R) classical Hodgkin Lymphoma (cHL) is well established, with PD-1 inhibitors such as pembrolizumab being a standard of care option for patients. ...
Prospective real-world outcomes of acute myeloid leukemia
(American Society of Hematology, 2023)
Background: It is evident that treatment outcomes improve with the clinical studies, in this study we aimed to investigate the demographics and treatment modalities of the acute myeloid leukemia (AML) patients in a large ...
Exploiting OTFS frame structure for PAPR reduction
(Institute of Electrical and Electronics Engineers Inc., 2022)
Wireless technologies have always been the cornerstone of industrial progress. However, as industrial technologies have improved and advanced services have emerged, the demands of industry have meant that wireless technologies ...
Turkish translation and crosscultural validity of WHOQoL-HIV Bref Tool
(Wiley, 2023)
...